Colchicine prophylaxis efficacy in PFAPA syndrome: A comparative cohort study
Authors' conclusion
Colchicine prophylaxis significantly reduces PFAPA attack frequency, with therapeutic benefits that are independent of FMF genetic status.
Study context
- Population
- Pediatric PFAPA patients
- Participants
- 55 patients
- Exposure
- Colchicine prophylaxis vs standard care alone
- Colchicinen = 15
- Standard caren = 40reference
- Outcome
- Change in inter-attack interval duration from baseline to study completion
Methodological detailscomparative cohort
- Comparative cohort
Main finding
As reported in the abstract
Change in inter-attack interval
Colchicine
60
median · IQR 51 · days
Standard care
0
median · IQR 0 · days
P < 0.001
Observational data: associations, not effects.
Further findings
Baseline FMF mutation prevalence
P = 0.002
Treatment response by FMF genetic status
- Colchicine's therapeutic benefit was consistent regardless of FMF genetic status
Original publication
Colchicine prophylaxis efficacy in PFAPA syndrome: A comparative cohort study. Semin Arthritis Rheum. Published 9 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →